MBX Biosciences, Inc.’s (NYSE:MBX) Quiet Period To End Tomorrow

MBX Biosciences’ (NYSE:MBX) quiet period will end on Wednesday, October 23rd. MBX Biosciences had issued 10,200,000 shares in its public offering on September 13th. The total size of the offering was $163,200,000 based on an initial share price of $16.00. During MBX Biosciences’ quiet period, underwriters and any insiders involved in the IPO are prevented from issuing any earnings forecasts or research reports for the company because of SEC regulations. Following the end of the company’s quiet period, the brokerages that served as underwriters will likely initiate research coverage on the company.

Wall Street Analysts Forecast Growth

Several equities analysts have recently issued reports on the company. Stifel Nicolaus assumed coverage on MBX Biosciences in a research note on Tuesday, October 8th. They set a “buy” rating and a $40.00 price target on the stock. Jefferies Financial Group started coverage on shares of MBX Biosciences in a research report on Tuesday, October 8th. They set a “buy” rating and a $35.00 target price on the stock. JPMorgan Chase & Co. started coverage on shares of MBX Biosciences in a research note on Tuesday, October 8th. They issued an “overweight” rating and a $30.00 target price on the stock. Finally, Guggenheim assumed coverage on shares of MBX Biosciences in a research note on Tuesday, October 8th. They set a “buy” rating and a $44.00 price target for the company.

MBX Biosciences Price Performance

Shares of MBX Biosciences stock opened at $23.89 on Tuesday. MBX Biosciences has a 12 month low of $20.29 and a 12 month high of $26.19.

Insider Transactions at MBX Biosciences

In other news, major shareholder Life Sciences X. L.P. Frazier acquired 625,000 shares of MBX Biosciences stock in a transaction that occurred on Monday, September 16th. The shares were acquired at an average price of $16.00 per share, with a total value of $10,000,000.00. Following the purchase, the insider now directly owns 4,552,774 shares of the company’s stock, valued at $72,844,384. The trade was a 0.00 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. In other MBX Biosciences news, major shareholder Life Sciences X. L.P. Frazier bought 625,000 shares of MBX Biosciences stock in a transaction on Monday, September 16th. The shares were purchased at an average cost of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the acquisition, the insider now owns 4,552,774 shares in the company, valued at approximately $72,844,384. The trade was a 0.00 % increase in their position. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website. Also, Director Edward T. Mathers bought 500,000 shares of the firm’s stock in a transaction on Monday, September 16th. The stock was acquired at an average cost of $16.00 per share, with a total value of $8,000,000.00. Following the completion of the purchase, the director now owns 3,614,486 shares of the company’s stock, valued at approximately $57,831,776. This trade represents a 0.00 % increase in their position. The disclosure for this purchase can be found here.

About MBX Biosciences

MBX Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism.